Piero Custodio-Sánchez

Piero Custodio-Sánchez

Auto-generated profile, based on publicly available information

Piero Custodio-Sánchez

Hospital Nacional Almanzor Aguinaga Asenjo - EsSalud. Unidad de cardiología intervencionista. Chiclayo, Perú. Hospital Nacional Almanzor Aguinaga Asenjo - EsSalud Unidad de cardiología intervencionista Chiclayo Perú

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 February 2021 in Vaccines
Verified
Journal Article
Open access
PDF file
ALAlvaro Sosa Liprandi
Alvaro Sosa Liprandi
EZEzequiel J Zaidel
Ezequiel J Zaidel
RLRicardo Lopez
Ricardo Lopez
JAJohn Jairo Araujo
John Jairo Araujo
MBManuel Alfonso Baños-González
Manuel Alfonso Baños-González
ABAdrian Marco Baranchuk
Adrian Marco Baranchuk
Background: Influenza vaccination (IV) and Pneumococcus vaccination (PV) are recommended for patients with cardiometabolic diseases. This study aimed to evaluate the immunization rate of ambulatory cardiometabolic patients during the COVID-19 pandemic in the Americas. Methods: Electronic surveys were collected from 13 Spanish speaking countries between 15 June and 15 July 2020. Results: 4216 patients were analyzed. Mean age 60 (±15) years and 49% females. Global IV rate was 46.5% and PV 24.6%. Vaccinated patients were older (IV = 63 vs. 58 years; PV = 68 vs. 59, p < 0.01) but without gender difference. Vaccination rates were greater in higher-risk groups (65+, diabetics, heart failure), but not in coronary artery disease patients. In the Southern cone, the rate of IV and PV was approximately double that in the tropical regions of the Americas. In a multivariate model, geographic zone (IV = OR 2.02, PV = OR 2.42, p < 0.001), age (IV = OR 1.023, PV = OR 1.035, p < 0.001), and incomes (IV = OR 1.28, PV = OR 1.58, p < 0.001) were predictors for vaccination. Conclusions: During the COVID-19 pandemic, ambulatory patients with cardiometabolic diseases from the Americas with no evidence of COVID-19 infection had lower-than-expected rates of IV and PV. Geographic, social, and cultural differences were found, and they should be explored in depth.

25 May 2021 in Archivos Peruanos de Cardiología y Cirugía Cardiovascular
Verified
Journal Article
Open access
PDF file
MCManuel Chacón-Diaz
Manuel Chacón-Diaz
RORené Rodríguez Olivares
René Rodríguez Olivares
DMDavid Miranda-Noé
David Miranda-Noé
PSPiero Custodio - Sánchez
Piero Custodio - Sánchez
ACAlexander Montesinos Cárdenas
Alexander Montesinos Cárdenas
AHAkram Hernández-Vásquez
Akram Hernández-Vásquez
Background. ST-segment elevation myocardial infarction (STEMI), is an important cause of morbidity and mortality worldwide, and myocardial reperfusion, when adequate, reduces the complications of this entity. The aim of the study was to describe the clinical and treatment characteristics of STEMI in Peru and the relationship of successful reperfusion with in-hospital adverse events. Materials and methods. Prospective, multicenter cohort of STEMI patients attended during 2020 in public hospitals in Peru. We evaluated the clinical, therapeutic characteristics and in-hospital adverse events, also the relationship between successful reperfusion and adverse events. Results. A total of 374 patients were included, 69.5% in Lima and Callao. Fibrinolysis was used in 37% of cases (pharmacoinvasive 26% and alone lysis 11%), primary angioplasty with < 12 hours of evolution in 20%, late angioplasty in 9% and 34% did not access adequate reperfusion therapies, mainly due to late presentation. Ischemia time was longer in patients with primary angioplasty compared to fibrinolysis (median 7.7 hours (RIQ 5-10) and 4 hours (RIQ 2.3-5.5) respectively). Mortality was 8.5%, the incidence of post-infarction heart failure was 27.8% and of cardiogenic shock 11.5%. Successful reperfusion was associated with lower cardiovascular mortality (RR:0.28; 95%CI: 0.12-0.66, p=0.003) and lower incidence of heart failure during hospitalization (RR: 0.61; 95%CI: 0.43-0.85, p=0.004). Conclusions. Fibrinolysis continues to be the most frequent reperfusion therapy in public hospitals in Peru. Shorter ischemia-to-reperfusion time was associated with reperfusion success, and in turn with fewer in-hospital adverse events.

21 December 2023 in Archivos Peruanos de Cardiología y Cirugía Cardiovascular
Verified
Journal Article
Open access
PDF file
PCPiero Custodio-Sánchez
Piero Custodio-Sánchez
DMDavid Miranda-Noé
David Miranda-Noé
LLL. Marco López-Rojas
L. Marco López-Rojas
CPCynthia Paola Paredes Paucar
Cynthia Paola Paredes Paucar
WGW. Germán Yábar Galindo
W. Germán Yábar Galindo
MCManuel Chacón-Diaz
Manuel Chacón-Diaz
ST-segment elevation myocardial infarction (STEMI) is a clinical entity whose adequate treatment will depend on its prompt recognition, accurate diagnosis, and management in reperfusion networks. The first contact with these patients is generally done in centers without reperfusion capacity, attended by non-cardiologist doctors, and in centers far from hospitals with greater resolution capacity, something that is well known in our country. This manuscript proposes a strategy for the diagnosis and treatment of STEMI in centers without percutaneous coronary intervention capacity of the public health system in Peru, emphasizing not losing sight of electrocardiographic patterns compatible with coronary artery occlusion, adequate fibrinolysis and management of its complications, the treatment of infarction in special populations and highlighting the importance of the pharmacoinvasive strategy as the main form of reperfusion treatment in our country.

9 July 2020 in Archivos Peruanos de Cardiología y Cirugía Cardiovascular
Verified
Journal Article
Open access
PDF file
PSPiero Custodio - Sánchez
Piero Custodio - Sánchez
DMDavid Miranda
David Miranda
LMLuis Murillo
Luis Murillo
Resumen Objetivo: Comparar el número de ingresos, características clínicas y resultados terapéuticos de los pacientes atendidos por infarto de miocardio con elevación del segmento ST (IMCEST) antes y durante el estado de emergencia por COVID-19 en Perú. Métodos: Se realizó un estudio descriptivo y comparativo de cohortes, derivadas del PEruvian Registry of ST-segment Elevation Myocardial Infarction II (PERSTEMI II). Se comparó los pacientes atendidos por IMCEST 45 días antes y durante los 45 días iniciales del estado de emergencia por COVID-19 en Perú. Resultados: Durante los primeros 45 días del período de emergencia se encontró una disminución del 59% en el número de ingresos por IMCEST. Hubo una mayor proporción de pacientes con antecedentes de hipertensión arterial y dislipidemia. Se observó una tendencia a reducción en el acceso a terapias de reperfusión (73.5% vs 66.6%), siendo la fibrinólisis la terapia más utilizada. El motivo más frecuente de no reperfusión fue la presentación tardía >24 horas (41.7%, p=0.004). Hubo una tendencia a reducción del tiempo al primer contacto médico y del tiempo de isquemia hasta la reperfusión. Se registró menor incidencia de falla cardíaca post infarto. La mortalidad fue similar en ambos grupos (3.4% vs 2.7%). Conclusiones: La pandemia por COVID-19 en el Perú ha generado una disminución significativa en los ingresos por IMCEST, además de una tendencia a menor empleo de terapias de reperfusión. La presentación tardía de los pacientes fue la causa más frecuente de no reperfusión.

22 September 2021 in Archivos Peruanos de Cardiología y Cirugía Cardiovascular
Verified
Journal Article
Open access
PDF file
JAJean Pierre Carrión Arcela
Jean Pierre Carrión Arcela
PCPiero Custodio-Sánchez
Piero Custodio-Sánchez
TCTatiana Gisell Coca Caycho
Tatiana Gisell Coca Caycho
Objetivo. Evaluar la repercusión de la pandemia del COVID-19 sobre el abordaje del infarto de miocardio con elevación del segmento ST (IMCEST) en un centro de referencia en el norte del Perú. Métodos. Se realizó un estudio observacional, analítico, tipo cohortes retrospectivas, derivado del registro de síndrome coronario agudo del Hospital Nacional Almanzor Aguinaga Asenjo. Se compararon las características de los pacientes con IMCEST y sus desenlaces a 30 días en dos cohortes según el momento de atención médica: previo a la pandemia o durante pandemia. Resultados. Durante la pandemia del COVID-19 disminuyeron las hospitalizaciones por IMCEST en 53%; hubo mayor empleo de fibrinólisis en detrimento de la angioplastia primaria, con incrementos en el tiempo de primer contacto médico (100 vs. 240 min, p= 0,006) y tiempo de isquemia hasta el intervencionismo coronario percutáneo (900 vs. 2880 min, p < 0,001). Se encontró mayor frecuencia de falla cardiaca posinfarto (21,1% vs. 46,7%, p= 0,002) y menor fracción de eyección del ventrículo izquierdo al alta (49,2 +/- 8,6 vs. 44,8 +/- 9,3, p= 0,009), sin que esto se refleje en un incremento de la mortalidad cardiovascular intrahospitalaria. Conclusiones. La pandemia COVID-19 ha tenido un impacto negativo en el abordaje de pacientes con IMCEST, disminuyó las hospitalizaciones y prolongó los tiempos de reperfusión generando mayor frecuencia de falla cardiaca posinfarto y menor fracción de eyección del ventrículo izquierdo al alta.

29 June 2022 in Archivos Peruanos de Cardiología y Cirugía Cardiovascular
Verified
Journal Article
Open access
PDF file
MCManuel Chacón-Diaz
Manuel Chacón-Diaz
AHAkram Hernández-Vásquez
Akram Hernández-Vásquez
PCPiero Custodio-Sánchez
Piero Custodio-Sánchez
Objectives. To determine one-year survival and factors associated with mortality in patients with STsegment elevation myocardial infarction in Peru. Methods. An analysis was made of the cohort of patients included in the PERSTEMI-II registry during the year 2020, in whom survival at one year after the event and its risk factors were evaluated using Kaplan-Meier survival analysis and Cox regression. Results. Of 374 patients in the PERSTEMI-II study, 366 (97.9%) completed follow-up up to one year after the event with a survival rate of 85%. Successful reperfusion was related to better survival at 1 year (hazard ratio [HR]=0.30, 95% CI: 0.14-0.62, p=0.001). Age (HR=1.04, 95% CI: 1.01-1.07, p=0.003), chronic kidney disease (HR=2.15, 95% CI: 1.04-4.39, p=0.037) and cardiogenic shock (HR=6.67, 95% CI: 3.72-11.97, p<0.001) were factors of higher mortality at 1-year follow-up. Conclusion. The PERSTEMIII registry is the first Peruvian registry that provides data on survival after ST-segment elevation myocardial infarction, which is 85% at one year. Successful reperfusion improves survival at one-year post infarction.